Target family: Calcium- and sodium-activated potassium channels (K<sub>Ca</sub>, K<sub>Na</sub>) (type: vgic)
Target: K<sub>Ca</sub>2.3

Ligand: UCL1848 (Synthetic organic)
Interaction type: Channel blocker
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 8.699999809265137 pIC50
Reference (Journal): SK3 is an important component of K(+) channels mediating the afterhyperpolarization in cultured rat SCG neurones.
Published in: J Physiol (Lond.)

Ligand: UCL1684 (Synthetic organic)
Interaction type: Inhibitor
Action: None
Ligand approved: no
Primary target: no
Median affinity:  pIC50
Reference (Journal): Calcium-activated potassium channels sustain calcium signaling in T lymphocytes. Selective blockers and manipulated channel expression levels.
Published in: J Biol Chem

Ligand: UCL1684 (Synthetic organic)
Interaction type: Inhibitor
Action: None
Ligand approved: no
Primary target: no
Median affinity:  pIC50
Reference (Journal): Small conductance calcium-activated potassium channels: from structure to function.
Published in: Prog Neurobiol

Ligand: UCL1684 (Synthetic organic)
Interaction type: Channel blocker
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 8.199999809265137 pIC50
Reference (Journal): SK3 is an important component of K(+) channels mediating the afterhyperpolarization in cultured rat SCG neurones.
Published in: J Physiol (Lond.)

Ligand: tubocurarine (Natural product)
Interaction type: Channel blocker
Action: Antagonist
Ligand approved: yes
Approval source: FDA (1945)
Primary target: no
Median affinity:  pIC50
Reference (Journal): Pharmacological characterisation of the human small conductance calcium-activated potassium channel hSK3 reveals sensitivity to tricyclic antidepressants and antipsychotic phenothiazines.
Published in: Neuropharmacology

Ligand: tubocurarine (Natural product)
Interaction type: Channel blocker
Action: Antagonist
Ligand approved: yes
Approval source: FDA (1945)
Primary target: no
Median affinity:  pIC50
Reference (Journal): An apamin- and scyllatoxin-insensitive isoform of the human SK3 channel.
Published in: Mol Pharmacol

Ligand: tetraethylammonium (Synthetic organic)
Interaction type: Channel blocker
Action: None
Ligand approved: no
Primary target: no
Median affinity: 2.700000047683716 pIC50
Reference (Journal): Small conductance calcium-activated potassium channels: from structure to function.
Published in: Prog Neurobiol

Ligand: tamapin (Peptide)
Interaction type: Channel blocker
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 8.800000190734863 pIC50
Reference (Journal): Tamapin, a venom peptide from the Indian red scorpion (Mesobuthus tamulus) that targets small conductance Ca2+-activated K+ channels and afterhyperpolarization currents in central neurons.
Published in: J Biol Chem

Ligand: SKA-31 (Synthetic organic)
Interaction type: Activator
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity: 5.519999980926514 pEC50
Reference (Journal): Naphtho[1,2-d]thiazol-2-ylamine (SKA-31), a new activator of KCa2 and KCa3.1 potassium channels, potentiates the endothelium-derived hyperpolarizing factor response and lowers blood pressure.
Published in: Mol Pharmacol

Ligand: riluzole (Synthetic organic)
Interaction type: Activator
Action: Agonist
Ligand approved: yes
Approval source: FDA (1995), EMA (1996)
Primary target: no
Median affinity: 4.900000095367432 pEC50
Reference (Journal): Naphtho[1,2-d]thiazol-2-ylamine (SKA-31), a new activator of KCa2 and KCa3.1 potassium channels, potentiates the endothelium-derived hyperpolarizing factor response and lowers blood pressure.
Published in: Mol Pharmacol

Ligand: riluzole (Synthetic organic)
Interaction type: Activator
Action: Agonist
Ligand approved: yes
Approval source: FDA (1995), EMA (1996)
Primary target: no
Median affinity:  -
Reference (Journal): Pharmacological modulation of SK3 channels.
Published in: Neuropharmacology

Ligand: RA-2 (Synthetic organic)
Interaction type: Gating inhibitor
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 7.699999809265137 pIC50
Reference (Journal): A novel pan-negative-gating modulator of KCa2/3 channels, fluoro-di-benzoate, RA-2, inhibits endothelium-derived hyperpolarization-type relaxation in coronary artery and produces bradycardia in vivo.
Published in: Mol Pharmacol

Ligand: P05 (Peptide)
Interaction type: Channel blocker
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 7.599999904632568 pIC50
Reference (Journal): Design and characterization of a highly selective peptide inhibitor of the small conductance calcium-activated K+ channel, SkCa2.
Published in: J Biol Chem

Ligand: NS8593 (Synthetic organic)
Interaction type: Gating inhibitor
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 6.099999904632568 pIC50
Reference (Journal): Inhibitory gating modulation of small conductance Ca2+-activated K+ channels by the synthetic compound (R)-N-(benzimidazol-2-yl)-1,2,3,4-tetrahydro-1-naphtylamine (NS8593) reduces afterhyperpolarizing current in hippocampal CA1 neurons.
Published in: Mol Pharmacol

Ligand: NS309 (Synthetic organic)
Interaction type: Activator
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity:  -
Reference (Journal): Activation of human IK and SK Ca2+ -activated K+ channels by NS309 (6,7-dichloro-1H-indole-2,3-dione 3-oxime).
Published in: Biochim Biophys Acta

Ligand: NS309 (Synthetic organic)
Interaction type: Activator
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity:  -
Reference (Journal): Small conductance calcium-activated potassium channels: from structure to function.
Published in: Prog Neurobiol

Ligand: NS13001 (Synthetic organic)
Interaction type: Activator
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity: 6.849999904632568 pEC50
Reference (Journal): Selective positive modulator of calcium-activated potassium channels exerts beneficial effects in a mouse model of spinocerebellar ataxia type 2.
Published in: Chem Biol

Ligand: NS11757 (Synthetic organic)
Interaction type: Gating inhibitor
Action: None
Ligand approved: no
Primary target: no
Median affinity: 8.100000381469727 pKd
Reference (Journal): Synthesis and structure-activity relationship studies of 2-(N-substituted)-aminobenzimidazoles as potent negative gating modulators ofsmall conductance Ca2+-activated K+ channels.
Published in: J Med Chem

Ligand: leiurotoxin I (Peptide)
Interaction type: Channel blocker
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity:  pIC50
Reference (Journal): An apamin- and scyllatoxin-insensitive isoform of the human SK3 channel.
Published in: Mol Pharmacol

Ligand: leiurotoxin I (Peptide)
Interaction type: Channel blocker
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 8.100000381469727 pIC50
Reference (Journal): SK3 is an important component of K(+) channels mediating the afterhyperpolarization in cultured rat SCG neurones.
Published in: J Physiol (Lond.)

Ligand: leiurotoxin I (Peptide)
Interaction type: Channel blocker
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity:  pIC50
Reference (Journal): Design and characterization of a highly selective peptide inhibitor of the small conductance calcium-activated K+ channel, SkCa2.
Published in: J Biol Chem

Ligand: Lei-Dab7 (Peptide)
Interaction type: Channel blocker
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 8.420000076293945 pKd
Reference (Journal): Design and characterization of a highly selective peptide inhibitor of the small conductance calcium-activated K+ channel, SkCa2.
Published in: J Biol Chem

Ligand: EBIO (Synthetic organic)
Interaction type: Activator
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity: 3.799999952316284 pEC50
Reference (Journal): Small conductance calcium-activated potassium channels: from structure to function.
Published in: Prog Neurobiol

Ligand: EBIO (Synthetic organic)
Interaction type: Activator
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity: 3.799999952316284 pEC50
Reference (Journal): An apamin- and scyllatoxin-insensitive isoform of the human SK3 channel.
Published in: Mol Pharmacol

Ligand: EBIO (Synthetic organic)
Interaction type: Activator
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity:  -
Reference (Journal): Pharmacological modulation of SK3 channels.
Published in: Neuropharmacology

Ligand: dequalinium (Synthetic organic)
Interaction type: Channel blocker
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 4.5 pIC50
Reference (Journal): Pharmacological characterisation of the human small conductance calcium-activated potassium channel hSK3 reveals sensitivity to tricyclic antidepressants and antipsychotic phenothiazines.
Published in: Neuropharmacology

Ligand: DC-EBIO (Synthetic organic)
Interaction type: Activator
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity: 4.900000095367432 pEC50
Reference (Journal): Modulators of small- and intermediate-conductance calcium-activated potassium channels and their therapeutic indications.
Published in: Curr Med Chem

Ligand: CyPPA (Synthetic organic)
Interaction type: Activator
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity: 5.300000190734863 pEC50
Reference (Journal): Selective positive modulation of the SK3 and SK2 subtypes of small conductance Ca2+-activated K+ channels.
Published in: Br J Pharmacol

Ligand: Ca2+ (Inorganic)
Interaction type: Activator
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity:  pEC50
Reference (Journal): Selective positive modulation of the SK3 and SK2 subtypes of small conductance Ca2+-activated K+ channels.
Published in: Br J Pharmacol

Ligand: Ca2+ (Inorganic)
Interaction type: Activator
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity:  pEC50
Reference (Journal): An apamin- and scyllatoxin-insensitive isoform of the human SK3 channel.
Published in: Mol Pharmacol

Ligand: Ca2+ (Inorganic)
Interaction type: Activator
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity: 6.199999809265137 pEC50
Reference (Journal): Cloning and functional expression of a liver isoform of the small conductance Ca2+-activated K+ channel SK3.
Published in: Am J Physiol, Cell Physiol

Ligand: Ca2+ (Inorganic)
Interaction type: Activator
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity:  pEC50
Reference (Journal): Mechanism of calcium gating in small-conductance calcium-activated potassium channels.
Published in: Nature

Ligand: apamin (Peptide)
Interaction type: Inhibitor
Action: None
Ligand approved: no
Primary target: no
Median affinity:  pIC50
Reference (Journal): Pharmacological characterisation of the human small conductance calcium-activated potassium channel hSK3 reveals sensitivity to tricyclic antidepressants and antipsychotic phenothiazines.
Published in: Neuropharmacology

Ligand: apamin (Peptide)
Interaction type: Channel blocker
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity:  pIC50
Reference (Journal): SK3 is an important component of K(+) channels mediating the afterhyperpolarization in cultured rat SCG neurones.
Published in: J Physiol (Lond.)

Ligand: apamin (Peptide)
Interaction type: Inhibitor
Action: None
Ligand approved: no
Primary target: no
Median affinity:  pIC50
Reference (Journal): An apamin- and scyllatoxin-insensitive isoform of the human SK3 channel.
Published in: Mol Pharmacol

Ligand: apamin (Peptide)
Interaction type: Channel blocker
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity:  pIC50
Reference (Journal): Cloning and functional expression of a liver isoform of the small conductance Ca2+-activated K+ channel SK3.
Published in: Am J Physiol, Cell Physiol